A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis

Fan, Tao; Lu, Zhiliang; Liu, Yu; Wang, Li-Yu; Tian, He; Yang, Zheng; Zheng, Bo; Xue, Liyan; Tan, Fengwei; Xue, Qi; Gao, Shugeng; Li, Chunxiang

doi:10.3389/fimmu.2021.665407

Cited by 22 publications

(16 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, high expression levels of KIF2C were associated with the poor prognosis of most cancers, which strongly suggested that KIF2C was a potential prognostic biomarker for tumor treatment. Tumorigenesis is a complex phenomenon, which is often caused by gene mutations (Fan et al, 2021). Based on this, we then studied the characteristics of KIF2C gene mutation.…”

Section: Discussionmentioning

confidence: 99%

Characterization of Kinesin Family Member 2C as a Proto-Oncogene in Cervical Cancer

Yang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Kinesin family member 2C (KIF2C) is known as an oncogenic gene to regulate tumor progression and metastasis. However, its pan-cancer analysis has not been reported. In this study, we comprehensively analyzed the characteristics of KIF2C in various cancers. We found that KIF2C was highly expressed and corresponded to a poor prognosis in various cancers. We also found a significant correlation between KIF2C and clinicopathological characteristics, particularly in cervical cancer, which is the most common gynecological malignancy and is the second leading cause of cancer-related deaths among women worldwide. KIF2C mutation is strongly associated with the survival rate of cervical cancer, and KIF2C expression was significantly upregulated in cervical cancer tissues and cervical cancer cells. Moreover, KIF2C promoted cervical cancer cells proliferation, invasion, and migration in vitro and as well increased tumor growth in vivo. KIF2C knockdown promotes the activation of the p53 signaling pathway by regulating the expression of related proteins. The rescue assay with KIF2C and p53 double knockdown partially reversed the inhibitory influence of KIF2C silencing on cervical cancer processes. In summary, our study provided a relatively comprehensive description of KIF2C as an oncogenic gene and suggested KIF2C as a therapeutic target for cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of Kinesin Family Member 2C as a Proto-Oncogene in Cervical Cancer

Yang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The occurrence and progression of cancer are linked to gene mutations (36). We further explored the characteristics of KIF2C gene mutations.…”

Section: Discussionmentioning

confidence: 99%

Large-Scale Transcriptome Data Analysis Identifies KIF2C as a Potential Therapeutic Target Associated With Immune Infiltration in Prostate Cancer

Zhang

Gao²,

Ye³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most prevalent cancers of the urinary system. In previous research, Kinesin family member 2C (KIF2C), as an oncogene, has been demonstrated to have a key role in the incidence and progression of different cancers. However, KIF2C has not been reported in PCa. We combined data from different databases, including The Cancer Genome Atlas, the Cancer Cell Line Encyclopedia, Genotype Tissue-Expression, cBioPortal, and the Genomics of Drug Sensitivity in Cancer database, to explore the potential oncogenic role of KIF2C in PCa through a series of bioinformatics approaches, including analysis of the association between KIF2C and prognosis, clinicopathological features, gene mutations, DNA methylation, immune cell infiltration, and drug resistance. The results showed that KIF2C was significantly up-regulated in PCa. High KIF2C expression was associated with age, pathological stage, lymph node metastases, prostate-specific antigen (PSA), and Gleason score and significantly predicted an unfavorable prognosis in PCa patients. Results from Gene Set Enrichment Analysis (GSEA) suggested that KIF2C was involved in the cell cycle and immune response. KIF2C DNA methylation was reduced in PCa and was inversely linked with KIF2C expression. KIF2C was shown to have a strong relationship with the tumor microenvironment (TME), infiltrating cells, and immune checkpoint genes. Furthermore, high KIF2C expression was significantly resistant to a variety of MAPK signaling pathway-related inhibitors. Our study reveals that KIF2C may be a possible predictive biomarker for assessing prognosis in PCa patients with immune infiltration.

show abstract

“…Fan et al nally validated the predictive value of the signature by tissue sample and that's what we need to do with the rest of our study. 45 Additionally, Hou and his colleagues also discussed the potential upstream regulator of DEGstranscription factors, but lacked functional enrichment and pathway analysis. 46 These studies, including ours, may provide a theoretical basis for more effective, individualized immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients

Liu

Shan

Zhao

et al. 2022

Preprint

View full text Add to dashboard Cite

Background. Lung Squamous Cell Carcinoma (LUSC) is an aggressive malignancy with limited therapeutic options. The response to immune therapy is a determining factor for the prognosis of LUSC patients. This study aimed to develop a reliable immune-related prognostic signature in LUSC.Methods. We extracted gene expression and clinical data of LUSC from The Cancer Genome Atlas (TCGA). A total of 502 patients enrolled and were divided into respond and non-respond groups by the TIDE algorithm. The CIBERSORT algorithm and the LM22 gene signature were used to analyze the distribution of immune cells in LUSC. Efficacy and response strength of immunotherapy are calculated by the tumor mutation burden (TMB) and ESTIMATE Score. Differentially expressed genes (DEGs) between the two groups were analyzed. The differential expression genes related to overall survival were pointed as hub DEGs, and a prognostic signature was constructed with lasso regression analysis.Results. LUSC patients were divided into responder and non-responder groups based on the response to immunotherapy. The distribution of immune cells was significantly different between the two groups. Forty-four DGEs were considered as overall survival-related genes. A prognostic signature was constructed, consisting of 11 hub-DGEs, including MMP20, C18orf26, CASP14, FAM71E2, OPN4, CGB5, DIRC1, C9orf11, SPATA8, C9orf144B, and ZCCHC5. The signature can accurately distinguish LUSC patients into high and low-risk groups. Moreover, the high-risk group had a shorter survival time than the low-risk group. The area under the ROC curve was 0.67. The multivariate Cox regression showed that the risk score calculated by the constructed signature was an independent prognostic predictor for LUSC patients.Conclusion. In short, we established a novel immune-related prognostic signature in LUCS, which has significant sensitivity and accuracy in predicting the prognosis of patients. Our research can guide the evaluation of the prognosis of LUSC patients in clinical, and the discovered immune-related genes can provide a theoretical basis for the discovery of new therapeutic targets.

show abstract

A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis

Cited by 22 publications

References 70 publications

Characterization of Kinesin Family Member 2C as a Proto-Oncogene in Cervical Cancer

Characterization of Kinesin Family Member 2C as a Proto-Oncogene in Cervical Cancer

Large-Scale Transcriptome Data Analysis Identifies KIF2C as a Potential Therapeutic Target Associated With Immune Infiltration in Prostate Cancer

Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients

Contact Info

Product

Resources

About